Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression
Tiziana Carandini, Anna M. Pietroboni, Luca Sacchi, Milena De Riz, Mattia Pozzato, Andrea Arighi, Giorgio Fumagalli, Filippo Martinelli Boneschi, Daniela Galimberti, Elio Scarpini
Topics & Concepts
AlemtuzumabImmunosuppressionPandemicMultiple sclerosisCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyInternal medicineAntibodyInfectious disease (medical specialty)DiseaseOutbreakMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and Disorders